You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The startup plans to harness single-cell genomics and computational analysis to discover therapies for autoimmune disease and cancer.
HTG Molecular will provide Firalis with technology and components to support its commercialization of a rheumatoid arthritis theranostic assay.
PredictImmune's test relies on a 16-marker panel run using quantitative PCR to stratify Crohn's disease and ulcerative colitis patients according to the severity of their illnesses.
The panel is designed to measure genetic markers in whole-blood samples in order to predict which patients are likely to experience a severe, relapsing form of the disease.
CytoReason's machine-learning algorithms extract information from multi-omic measurements to improve indication prioritization and highlight new treatment targets.
The team used genetic scoring to identify infants without a family history of the disease who had more than a 10 percent risk for developing islet antibodies.
Cincinnati Children's Hospital Medical Center researchers found that disease risk loci overlap with transcription factor binding sites.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
The company's new effort, DigitalMe, has recruited more than 5,000 participants so far, tracking patient health reports alongside genomics and repeat blood biomarker measurements.
The Boston-based startup wants to help individuals interpret their HLA data for ancestry and health, and participate in research studies.
New research suggests that some risky and protective variants in the LRRK2 gene have shared genetic effects in Crohn's disease and Parkinson's disease.
Qualified patients will have immediate access to IQuity's MS test, with expected access later to an IBD-IBS test, and a fibromyalgia test.
Theradiag's Lisa Tracker monitoring kits will be referenced in supply contracts for Merck's immunosuppressant drug.
The study aims to identify genetic markers of multiple sclerosis, including ones that can be used for disease diagnosis.
The partners are initially planning to make searchable whole-genome data and EMRs from more than 1,000 rheumatoid arthritis patients accessible to trial developers.
Examining five types of bacterial environments in patients' stomachs, researchers found that non-Helicobacter pylori microbiota may lead to gastric cancer development.
The researchers found disease-related signatures in the immune repertoire of affected patients as well as changes associated with treatment.
A pair of studies has established a potential role for specific gut bacteria in the progression of MS, suggesting therapeutic targeting of the microbiota as a potential treatment.
The researchers used this approach to show how non-coding variation associated with human immune dysfunction alters context-specific gene programs.
The newly announced Microbiome Immunity Project seeks to discover links between autoimmune diseases and bacteria in and on the human body.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.